However , an analysis of age groups revealed the benefits of DEXA in children younger than 14 years ( the event-free survival ( EFS ) was 762 and 712 % , respectively ( p = 0.048 ) ; the overall survival ( OS ) was 812 and 772 % , respectively ( p = 0.046 ) ; therapy-induced mortality was 6.4 % ( DEXA ) andl 1.1 % ( MePRED ) ( p = 0.01 4 ) ; the rate of isolated extramedullary relapses was 1.5 % ( DEXA ) and 4.4 % ( MePRED ) ( p = 0.009 ) .